

**LISTING OF THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1. (Currently Amended) The compound 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-[[ $\alpha$ ]] 7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate.

Claim 2. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ) exhibiting an X-ray powder diffraction pattern having characteristic reflexes (expressed in degrees of diffraction angle  $2\theta$ ) at approximately: 9.0, 10.0, 12.8, 15.9, 18.1, 18.8, 19.8, 20.1, 21.8, 23.7.

Claim 3. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ), characterized by an X-ray powder diffraction pattern shown in FIG. 1.

Claim 4. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ), exhibiting an infrared spectrum recorded in attenuated total reflectance having characteristic absorption bands expressed in reciprocal centimeters at approximately: 3246, 1644, 1455, 1381, 1368, 1292, 1117, 1092, 1042, 743.

Claim 5. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ), characterized by a complete infrared spectrum shown in FIG. 2.